1
Stoffel Markus, Manoharan Muthiah, Rajeev Kallanthottathil G: Chemically modified oligonucleotides for use in modulating micro rna and uses thereof. The Rockefeller University, Alnylam Pharmaceuticals, Stoffel Markus, Manoharan Muthiah, Rajeev Kallanthottathil G, NGUYEN Quang D, July 31, 2008: WO/2008/091703 (18 worldwide citation)

This invention relates generally to chemically modified oligonuceotides useful for modulating expression of microRNAs and pre-microRNAs. More particularly, the invention relates to single stranded chemically modified oligonuceotides for inhibiting microRNA and pre-microRNA expression and to methods ...


2
FEIND DAVID E: Antimicrobial cationic stereoids and methods of use. THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA CENTER FOR TECHNOLOGY TRANSFER, Nguyen Quang D, September 9, 2011: WO/2011/109704 (13 worldwide citation)

The invention relates generally to antimicrobial cationic steroid pharmaceutical compositions, methods of making antimicrobial cationic steroid pharmaceutical compositions, and methods of using antimicrobial cationic steroi pharmaceutical compositions.


3
JUNE Carl H, LEVINE Bruce L, PORTER David L, KALOS Michael D: UTILISATION DE LYMPHOCYTES T MODIFIÉS PAR UN RÉCEPTEUR CHIMÉRIQUE DANTIGÈNES CHIMÉRIQUE POUR TRAITER LE CANCER, USE OF CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS TO TREAT CANCER. THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, JUNE Carl H, LEVINE Bruce L, PORTER David L, KALOS Michael D, NGUYEN Quang D, June 14, 2012: WO/2012/079000 (12 worldwide citation)

The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a ...


4
KATSIKIS Peter D, KINNEY William A, ALMOND Harold R, KHAN Noshena: [fr] NOUVEAUX INHIBITEURS DE PI3K P110 ET LEURS PROCÉDÉS DUTILISATION, [en] NOVEL PI3K p110 INHIBITORS AND METHODS OF USE THEREOF. PHILADELPHIA HEALTH & EDUCATION CORPORATION, INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH, NGUYEN Quang D, June 20, 2013: WO/2013/090725 (6 worldwide citation)

[en] The invention includes compositions that regulated PI3K p110 delta and are useful as an anti-viral therapy. The invention includes a method of inhibiting p110 delta, a component of PI3K p110 delta signaling pathway, or any combination thereof in a cell as an anti-viral therapeutic approach for ...


5
POWELL Daniel J, COUKOS George, JUNE Carl H: COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT DU CANCER, COMPOSITIONS AND METHODS FOR TREATING CANCER. THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, POWELL Daniel J, COUKOS George, JUNE Carl H, NGUYEN Quang D, July 26, 2012: WO/2012/099973 (6 worldwide citation)

The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having a-folate receptor (FRα) binding domain and 4- IBB (CD137) costimulatory domain to treat ovarian cancer.


6

7
KATSIKIS PETER D: The role of p110 delta signaling in morbidity and lung pathology induced by influenza virus infection. PHILADELPHIA HEALTH AND EDUCATION CORPORATION, Nguyen Quang D, July 22, 2010: WO/2010/083163 (5 worldwide citation)

The invention includes compositions and methods for regulating p110 delta as an anti-influenza virus therapy. The invention includes inhibiting p110 delta, a component of p110 delta signaling pathway, or any combination thereof in a cell as an anti-influenza viral therapeutic approach for treating i ...


8
KIRIAKIDOU Marianthi, GARCHOW Barry, KAUPPINEN Sakari: [fr] UTILISATION DE COMPOSÉS DACIDE NUCLÉIQUE BLOQUÉ (LNA) POUR LINHIBITION THÉRAPEUTIQUE DE MIR-21 DANS LE LUPUS ÉRYTHÉMATEUX SYSTÉMIQUE, [en] USE OF LNA COMPOUNDS FOR THERAPEUTIC INHIBITION OF MIR-21 IN SYSTEMIC LUPUS ERYTHEMATOSUS. KIRIAKIDOU Marianthi, GARCHOW Barry, KAUPPINEN Sakari, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, NGUYEN Quang D, January 24, 2013: WO/2013/013165 (3 worldwide citation)

[en] The present invention encompasses compositions of LNA antimiRs as well as methods of their use for the regulation of miR-21 expression. The present invention encompasses methods of treating diseases where miR-21 is up-regulated. An example of such a disease is Systemic Lupus Erythematosus (SLE) ...


9
Lelkes Peter, Finck Christine M, Mondrinos Mark J: Engineered lung tissue construction for high throughput toxicity screening and drug discovery. Drexel University, Lelkes Peter, Finck Christine M, Mondrinos Mark J, NGUYEN Quang D, August 21, 2008: WO/2008/100555 (3 worldwide citation)

The present invention relates to compositions comprising fetal pulmonary cells and biocompatible materials. The present invention also provides an engineered three dimensional lung tissue exhibiting characteristics of a natural lung tissue. The engineered tissue is useful for the study of lung devel ...


10
POWELL Daniel J Jr, SCHOLLER Nathalie: [fr] RÉCEPTEUR IMMUNITAIRE CHIMÉRIQUE SPÉCIFIQUE COMPLÈTEMENT HUMAIN, ANTI-MÉSOTHÉLINE POUR UN CIBLAGE REDIRIGÉ DE CELLULES EXPRIMANT LA MÉSOTHÉLINE, [en] A FULLY HUMAN, ANTI-MESOTHELIN SPECIFIC CHIMERIC IMMUNE RECEPTOR FOR REDIRECTED MESOTHELIN-EXPRESSING CELL TARGETING. POWELL Daniel J Jr, SCHOLLER Nathalie, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, NGUYEN Quang D, May 2, 2013: WO/2013/063419 (3 worldwide citation)

[en] The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with dysregulated expression of mesothelin. In one embodiment, the invention relates to a fully human chimeric antigen receptor (CAR) wherein the CAR is able to target mesothelin.



Click the thumbnails below to visualize the patent trend.